Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation
25 Mars 2024 - 7:05AM
Nyxoah Advances Patient Access Strategy
through Partnership with the American Association of Otolaryngology
– Head & Neck Surgery FoundationFirst medical device
company to become a corporate champion at the ENTerprise Circle
level
Mont-Saint-Guibert, Belgium – March 25,
2024, 7:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced that the Company has signed a strategic partnership to
become a Corporate Champion at the ENTerprise Circle level with the
American Association of Otolaryngology – Head & Neck Surgery
Foundation (AAO-HNSF). Nyxoah is the first medical device company
to partner with the AAO-HNSF at this level.
The AAO-HNSF is committed to identifying and
combating harmful coverage policies that threaten access to quality
otolaryngology-head and neck services. The Academy’s Advocacy team,
in collaboration with its dedicated members and strategic industry
partners like Nyxoah, actively engage with payers to achieve this
goal.
The ENTerprise Circle is the top-tier
partnership experience and the collaboration will focus on
improving patient access to new breakthrough treatments for OSA
by:
- Navigating the CMS and Private
Payers prior authorization requirements pathway
- Preparing for interaction with the
FDA and AMA CPT to expand patient access to appropriate care
- Advocating for reducing the hurdles
to new, bilateral hypoglossal nerve stimulation (HGNS) therapy with
clinical guidelines to be used by CMS and commercial insurance
payers
"We are thrilled to partner with Nyxoah, the
maker of Genio,” said Dr James Denneny III, Executive Vice
President & CEO, AAO-HNSF. “With the rapid growth of HGNS, ENTs
are playing an increasingly important role in treating OSA. Genio
represents the next generation of HGNS technology and the AAO-HNSF
looks forward to working closely with Nyxoah to ensure all patients
in the U.S. have access to the system.”
“We are honored to be the first medical device
company to partner with the AAO-HNSF as a Corporate Champion at the
ENTerprise Circle level,” commented Olivier Taelman, Nyxoah’s Chief
Executive Officer. “Nyxoah and the AAO-HNSF share the common goal
of putting patients first and making sure they have access to HGNS
therapy. We look forward to working closely with the AAO-HNSF as we
prepare for our U.S. launch.”
About the AAO-HNSThe American
Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) is one of
the world’s largest organizations representing specialists who
treat the ears, nose, throat, and related structures of the head
and neck. Otolaryngologist–head and neck surgeons diagnose and
treat medical disorders that are among the most common affecting
patients of all ages in the United States and around the world.
Those medical conditions include chronic ear disease, hearing and
balance disorders, hearing loss, sinusitis, snoring and sleep
apnea, allergies, swallowing disorders, nosebleeds, hoarseness,
dizziness, and tumors of the head and neck as well as aesthetic and
reconstructive surgery and intricate micro-surgical procedures of
the head and neck. The Academy has approximately 13,000
members.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company's or, as appropriate,
the Company directors' or managements' current expectations
regarding the Genio® system; planned and ongoing clinical studies
of the Genio® system; the potential advantages of the Genio®
system; Nyxoah’s goals with respect to the development, regulatory
pathway and potential use of the Genio® system; the utility of
clinical data in potentially obtaining FDA approval of the Genio®
system; and the Company's results of operations, financial
condition, liquidity, performance, prospects, growth and
strategies. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that
could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely
affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set
forth in the “Risk Factors” section of the Company’s Annual Report
on Form 20-F for the year ended December 31, 2023, filed with the
Securities and Exchange Commission (“SEC”) on March 20, 2024, and
subsequent reports that the Company files with the SEC. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Contacts:NyxoahDavid DeMartino,
Chief Strategy Officerdavid.demartino@nyxoah.com+1 310 310 1313
Nyxoah (NASDAQ:NYXH)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Nyxoah (NASDAQ:NYXH)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024